Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic targeting of metabolic vulnerabilities in cancers with MLL3/4-COMPASS epigenetic regulator mutations.

The Journal of clinical investigation - 3 Jul 2023

Zhao Zibo, Cao Kaixiang, Watanabe Jun, Philips Cassandra N, Zeidner Jacob M, Ishi Yukitomo, Wang Qixuan, Gold Sarah R, Junkins Katherine, Bartom Elizabeth T, Yue Feng, Chandel Navdeep S, Hashizume Rintaro, Ben-Sahra Issam, Shilatifard Ali

Abstract excerpt

Epigenetic status-altering mutations in chromatin-modifying enzymes are a feature of human diseases, including many cancers. However, the functional outcomes and cellular dependencies arising from these mutations remain unresolved. In this study, we investigated cellular dependencies, or vulnerabilities, that arise when enhancer function is compromised by loss of the frequently mutated COMPASS family members MLL3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenesis, Genetic
Share to Histone-Lysine N-Methyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to Proteomics

Source

Open in PubMed Open full text

Identifiers

PMID: 37252797
DOI: 10.1172/JCI169993
PMCID: PMC10313365

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic targeting of metabolic vulnerabilities in cancers with MLL3/4-COMPASS epigenetic regulator mutations.PMID 37252797Read ↗

Enhancer and metabolic rewiring by KMT2C-COMPASS or KMT2D-COMPASS family loss in cancer creates druggable vulnerabilities.Semantic proximity Read ↗

Super-enhancer impairment is a link between MLL4-inactivated lung tumors and their vulnerability to glycolysis pathway inhibitionSemantic proximity Read ↗

Somatic mutations of MLL4/COMPASS induce cytoplasmic localization providing molecular insight into cancer prognosis and treatment.Semantic proximity Read ↗

ACSL4-Associated Lipid Metabolism is a Distinct Therapeutic Vulnerability in KMT2A-Rearranged Acute Myeloid LeukemiaSemantic proximity Read ↗

Metabolic defects provide a spark for the epigenetic switch in cancerSemantic proximity Read ↗

KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.Semantic proximity Read ↗

The germline factor DDX4 contributes to the chemoresistance of small cell lung cancer cellsSemantic proximity Read ↗

Unbiased functional genetic screens reveal essential RNA modifications in human cancer and drug resistanceSemantic proximity Read ↗

Enterocyte-like differentiation defines metabolic gene signatures of CMS3 colorectal cancers and provides therapeutic vulnerability.Semantic proximity Read ↗

Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy.Semantic proximity Read ↗

The PRMT5-splicing axis is a critical oncogenic vulnerability that regulates detained intron splicingSemantic proximity Read ↗

Epigenetic reprogramming induced by key metabolite depletion is an evolutionarily ancient path to tumorigenesis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.